A detailed history of Bank Of America Corp transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 84,036 shares of ITOS stock, worth $942,883. This represents 0.0% of its overall portfolio holdings.

Number of Shares
84,036
Previous 55,747 50.75%
Holding current value
$942,883
Previous $760,000 64.08%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$10.33 - $18.09 $292,225 - $511,748
28,289 Added 50.75%
84,036 $1.25 Million
Q1 2024

May 15, 2024

SELL
$9.89 - $13.64 $88,327 - $121,818
-8,931 Reduced 13.81%
55,747 $760,000
Q4 2023

Feb 14, 2024

SELL
$8.57 - $11.06 $438,664 - $566,117
-51,186 Reduced 44.18%
64,678 $708,000
Q2 2023

Aug 14, 2023

SELL
$12.93 - $18.05 $540,034 - $753,876
-41,766 Reduced 26.5%
115,864 $1.53 Million
Q1 2023

May 12, 2023

SELL
$13.02 - $22.62 $4.1 Million - $7.12 Million
-314,885 Reduced 66.64%
157,630 $2.15 Million
Q4 2022

Feb 10, 2023

BUY
$17.77 - $21.6 $2.25 Million - $2.73 Million
126,495 Added 36.56%
472,515 $9.23 Million
Q3 2022

Nov 14, 2022

BUY
$18.6 - $27.25 $3.64 Million - $5.33 Million
195,774 Added 130.3%
346,020 $6.59 Million
Q2 2022

Aug 12, 2022

BUY
$16.57 - $35.1 $176,752 - $374,411
10,667 Added 7.64%
150,246 $0
Q1 2022

May 16, 2022

BUY
$31.92 - $47.45 $1.61 Million - $2.4 Million
50,521 Added 56.73%
139,579 $4.49 Million
Q4 2021

Feb 08, 2022

BUY
$26.23 - $47.86 $1.75 Million - $3.19 Million
66,694 Added 298.22%
89,058 $4.15 Million
Q3 2021

Nov 15, 2021

BUY
$23.91 - $29.58 $345,451 - $427,371
14,448 Added 182.52%
22,364 $604,000
Q2 2021

Sep 13, 2021

BUY
$17.9 - $36.1 $141,696 - $285,767
7,916 New
7,916 $203,000

Others Institutions Holding ITOS

About iTeos Therapeutics, Inc.


  • Ticker ITOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,575,300
  • Market Cap $399M
  • Description
  • Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...
More about ITOS
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.